Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Blue Trust Inc.

Blue Trust Inc. grew its stake in Edwards Lifesciences Co. (NYSE:EW) by 59.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,049 shares of the medical research company’s stock after purchasing an additional 2,998 shares during the quarter. Blue Trust Inc.’s holdings in Edwards Lifesciences were worth $531,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after buying an additional 2,390,137 shares during the last quarter. CCLA Investment Management grew its position in shares of Edwards Lifesciences by 100,739.7% during the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock valued at $134,092,000 after buying an additional 1,405,319 shares during the last quarter. Swedbank AB bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $124,511,000. Sei Investments Co. grew its position in shares of Edwards Lifesciences by 162.7% during the 1st quarter. Sei Investments Co. now owns 1,465,719 shares of the medical research company’s stock valued at $140,064,000 after buying an additional 907,688 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several recent analyst reports. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $102.00 to $70.00 in a research report on Thursday, July 25th. Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Fifteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Stock Down 1.2 %

Shares of NYSE:EW opened at $69.24 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The company has a market cap of $41.72 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a 50 day simple moving average of $67.96 and a 200 day simple moving average of $78.76.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.66 EPS. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.